NAD refers Maxam Nutraceuticals to FTC

NEW YORK — The National Advertising Division has referred advertising claims made by Maxam Nutraceuticals for its PCA dietary supplement to the Federal Trade Commission for further review, after the company declined to participate in a review of its claims.

The Council for Responsible Nutrition challenged claims made by Maxam in television and Internet advertising, including:

“PCA is the only product ever specifically developed to naturally help your body safely and effectively remove all toxins, poisons, chemicals or anything that is not part of a healthy living biological system.”;

“PCA has been used and proven over the last 15 years to be the most effective toxin remover available.”; and

“Through our SMART Selective Micro-Activated Response Technology, the ingredients remain in their natural form, which keeps the liver from repelling them, allowing them to effectively work with your body.”

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

NEW YORK — Green Pharmaceuticals has drummed up some brand awareness for its SnoreStop stop-snoring solution with a controversial ad on Sunset Blvd. in Los Angeles, The Daily News reported last week.

The ad depicts an American soldier and Muslim woman who is wearing a wedding band accompanied by the hash-tag #betogether. "With this new campaign, we wanted to celebrate diversity, celebrate equality … by bringing into our campaign values coming from every corner of life," reported Christian DeRivel, Green Pharmaceutical chief branding officer, in a behind-the-scenes video on the campaign.

This is not the first time Green Pharmaceuticals has generated buzz for its brands through a newsworthy ad campaign. In 2005, Green paid more than $37,000 for the right to tattoo an advertisement on the forehead of Andrew Fischer. Fischer had placed his advertising real estate up for bid on eBay. Fischer sported a temporary SnoreStop tattoo for 30 days.

Reuters: Question on whether emergency contraceptives less effective in women weighing more than 165 lbs.

NEW YORK — The Food and Drug Administration is reviewing emergency contraceptives like Plan B One-Step on whether they are less effective in women weighing more than 165 lbs., according to a report published Monday by Reuters.

FDA’s impetus was the fact that European health regulators recently required a label change communicating that a similar emergency contraceptive began losing effectiveness in women who weighed 165 lbs. The emergency contraceptive did not work for women weighing more than 176 lbs, Reuters reported.

The emergency contraceptive that came under question in Europe is HRA Pharma’s Norlevo.

RELATED NEWS

Coming toward the end of the calendar year, there will be many consumers perusing purchases of over-the-counter medicines and devices in an effort to deplete their flexible spending accounts, many of which still contain a “use-it-or-lose-it” provision.

Private label just keeps chugging along.
Thanks to strong consumer demand for lower-priced alternatives to national brands and retailer desires to differentiate themselves from the competition, private label seems to keep gaining more traction in the retail world.

In a Journal of Advanced Nursing study of 90 adults with type 2 diabetes published last week, female gender, elevated blood sugar levels, neuropathic pain, and fatigue were related to sleep disturbance, even after controlling for factors such as age, diabetes duration, depressive symptoms and distress.

Ascensia Diabetes Care, based out of Basel, Switzerland, is showing its support for World Diabetes Day 2017 by publishing 30 portraits of inspiring women who are making significant contributions to advancing diabetes care.

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry